GlassScriptPhysician profile
Janel Jesberger
NPI 1760928204
$8,345.10
in general payments reported to CMS, 2019-2025
37 companies · $1,604 in 2025
The $1,604 reported for 2025 was more than what 88% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,415 · 2024: $5,326 · 2025: $1,604.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,915 · Travel and Lodging: $1,430.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,914.94 |
| Travel and Lodging | $1,430.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $2,313.13 | 2023-2025 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Abbvie INC. | $1,029.43 | 2023-2025 | |
| Pfizer INC. | $803.29 | 2023-2025 | |
| Ucb, INC. | $478.43 | 2023-2025 | Fintepla, Nayzilam, Briviact |
| Alexion Pharmaceuticals, INC. | $345.82 | 2023-2025 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $316.39 | 2023-2025 | |
| Sk Life Science, INC. | $309.59 | 2023-2025 | Xcopri |
| Biogen, INC. | $305.77 | 2023-2025 | Vumerity, Tysabri, Skyclarys |
| Emd Serono, INC. | $289.28 | 2024-2025 | Mavenclad |
| Argenx US, INC. | $212.96 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Teva Pharmaceuticals USA, INC. | $160.13 | 2023-2025 | Austedo Xr, Austedo Xr |
| Lundbeck LLC | $153.67 | 2023-2025 | Vyepti, Rexulti |
| Tg Therapeutics, INC. | $147.32 | 2023-2025 | |
| Lilly USA, LLC | $144.52 | 2024 | Emgality, Reyvow, Kisunla |
| Eisai INC. | $144.09 | 2024 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $128.45 | 2024-2025 | Ingrezza |
| Celgene Corporation | $124.50 | 2023-2025 | Zeposia |
| Genentech USA, INC. | $118.85 | 2023-2025 | Ocrevus Zunovo, Ocrevus |
| Neurelis, INC. | $112.83 | 2024-2025 | Valtoco |
| Merz Pharmaceuticals, LLC | $111.59 | 2023-2025 | Xeomin |
| Csl Behring | $68.21 | 2024 | Hizentra |
| Amgen INC. | $65.61 | 2023-2025 | Uplizna, Aimovig |
| Nevro Corp. | $57.25 | 2023-2024 | Senza |
| Mdd US Operations, LLC | $42.53 | 2024 | Gocovri |
| Ani Pharmaceuticals, INC. | $41.81 | 2024-2025 | Purified Cortrophin Gel |
| Banner Life Sciences, LLC | $41.12 | 2023-2024 | |
| Vanda Pharmaceuticals INC. | $37.63 | 2024 | Ponvory |
| Ipsen Biopharmaceuticals, INC | $32.79 | 2024 | Dysport |
| Scilex Pharmaceuticals INC. | $32.07 | 2023-2024 | Ztlido |
| Cycle Pharmaceuticals INC | $29.53 | 2025 | Tascenso Odt |
| Acorda Therapeutics, INC | $28.95 | 2023 | Inbrija |
| Otsuka America Pharmaceutical, INC. | $25.10 | 2024 | Rexulti |
| Kyowa Kirin, INC. | $22.93 | 2024 | Nourianz |
| Catalyst Pharmaceuticals, INC. | $20.23 | 2024 | |
| Acadia Pharmaceuticals INC | $18.14 | 2023 | Nuplazid |
| Tanabe Pharma America, INC. | $17.87 | 2023 | |
| Amneal Pharmaceuticals LLC | $13.29 | 2024 | Rytary |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janel Jesberger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.